Nevo-Shenker, Michal
Phillip, Moshe
Nimri, Revital
Shalitin, Shlomit
Article History
Received: 8 May 2019
Revised: 29 September 2019
Accepted: 13 October 2019
First Online: 12 November 2019
Competing interests
: M.N.S. has nothing to disclose. M.P. reports grants and personal fees from Sanofi, grants and personal fees from Medtronic, grants and personal fees from Novo Nordisk, grants and personal fees from Eli Lilly, grants from Merck, grants and personal fees from Pfizer, personal fees from DreaMed-Diabetes Ltd., grants from Kamada, grants from Dexcom, personal fees from Roche, personal fees from Sandoz, personal fees from Abbott, grants and personal fees from NG Solutions, grants and personal fees from Nutriteen Professionals Ltd. In addition, M.P. has a patent DreaMed-Diabetes Ltd. licensed. However, none of the above pertains to this submitted manuscript, for which no fees were received. R.N. reports grants from Medtronic, Novo Nordisk, Dexcom, and Abbott and personal fees from Eli Lilly and DreaMed-Diabetes Ltd. In addition R.N. has a patent DreaMed-Diabetes Ltd. licensed. However, none of the above pertains to this submitted manuscript, for which no fees were received. S.S. has nothing to disclose.